We have previously demonstrated that CD4 cross-linking (CD4XL) results in apoptosis of CD4+ T cells and augmentation of Fas antigen (CD95, APO-1) expression in CD4+ and CD8+ T cells. Here we demonstrate that CD4XL mediated by both, anti-CD4 monoclonal antibody (MoAb) or human immunodeficiency virus (HIV) envelope protein gp120 reduces the expression of the proto-oncogene Bcl-2 in CD4+ T cells, but not in CD8+ T cells, concurrently with the induction of CD4+ T cell-apoptosis. Additionally, the Bcl-2dim population expressed high levels of Fas antigen. Bax, an antagonist of Bcl-2, was brightly expressed even in the Bcl-2dim population. Addition of interleukin (IL)-2 rescued CD4+ T cells from CD4XL-induced Bcl-2 downmodulation and apoptosis induction. These results support the hypothesis that CD4 ligation by HIV-1 envelope protein in vivo in HIV-infected patients selectively reduces Bcl-2 protein in CD4+ T lymphocytes, thereby facilitating Fas/Fas-ligand triggered apoptosis; furthermore the findings reported expand the rationale for use of IL-2 in HIV disease.

ACCELERATED SPONTANEOUS and activated-induced T-cell apoptosis has been well documented in peripheral blood lymphocytes,1-3 as well as in the lymph nodes of human immunodeficiency virus (HIV)-infected individuals.4,5 Although the mechanisms involved in this accelerated apoptosis have not yet been fully elucidated, HIV-1 envelope protein-mediated CD4 cross-linking (CD4XL) is an attractive explanation for the depletion of CD4+ T cells. We previously demonstrated that: (1) CD4XL performed in peripheral blood mononuclear cells (PBMC) results in apoptosis of CD4+ T cells3, (2) CD4XL-induced apoptosis of CD4+ T cells requires the presence of accessory cells such as monocytes3, (3) CD4XL augments Fas antigen (CD95, APO-1) expression in CD4+ and CD8+ T cells6 and, (4) CD4XL induces tumor necrosis factor (TNF)-α and interferon (IFN)-γ, but not interleukin (IL)-2 secretion.6 Moreover, we recently discovered that the Fas-ligand (FasL) expression was augmented in monocytes after CD4XL.7 These results suggest that CD4XL is a potent mechanism for upregulating the proapoptotic molecules Fas and FasL, which are pivotal for initiating the apoptosis signaling pathway, and which are known to be upregulated in HIV infection.8-13 

The balance between life and death by apoptosis, however, is controlled by opposing forces of proapoptotic and antiapoptotic factors. The proto-oncogene Bcl-2 is known to protect cells against many forms of programmed cell death and induced cell death, including growth factor deprivation (reviewed in Wyllie,14 Henkart,15 and Nunez16 ) and was originally cloned from the breakpoint of a t(14; 18) translocation present in many human B cell lymphomas.17,18 Additionally, many investigators have reported an inverse relationship of Fas antigen and Bcl-2 protein in peripheral lymphocytes and tumor cell lines.19-22 We demonstrate here that CD4XL in PBMC, which results in apoptosis induction, reduces the Bcl-2 expression in CD4+ T cells, but not in CD8+ T cells. Also, our results show that the Bcl-2dim population clearly expresses higher levels of Fas antigen than the Bcl-2bright population. Furthermore, IL-2, a known inducer of Bcl-223, rescues the CD4XL-induced CD4+ T lymphocyte apoptosis by preventing Bcl-2 downmodulation.

Cells and culture conditions.PBMC from healthy individuals were isolated from heparinized venous blood by Ficoll-Hypaque density gradient centrifugation (Accu-Prep, Accurate Chemical, Westbury, NY) as recently described.3 RPMI 1640 (GIBCO Laboratories, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (FCS; GIBCO), 2 mmol/L L-glutamine (BIOWHITTAKER, Inc, Walkersville, MD), 100 U/mL penicillin G, and 100 μg/mL streptomycin was used for all cultures.

Antibodies and reagents. Reagents and sources were as follows: monoclonal antibody (MoAb) to CD4 (Leu3a; IgG1; Becton Dickinson, Mountain View, CA); goat antimouse Ig (GAM; Tago, Inc, Burlingame CA); mouse Igs from nonimmunized animals (nonimmune IgGs; ChromPure IgG; Jackson ImmunoResearch Lab, West Grove, PA); phytohemagglutinin (PHA, 10.5 μg/ml, Difco, Detroit, MI); recombinant human IL-2 (Boehringer Mannheim, Indianapolis, IN). The native HIV-1 envelope protein gp120 was purified from supernatants of human T-cell leukemia virus type III451-infected 6D5 cells, as described previously.24 Rabbit anti-gp120 (HIV-1IIIB) polyclonal antibodies were obtained from American Bio Technologies (Cambridge, MA).

Induction of CD4 cross-linking. Cells were treated as described3 with Leu3a or control antibody at concentrations of 3 μg/2 × 106 cells for 40 minutes at 4°C and cultured in round-bottom 12 × 75 mm polystyrene tubes (Falcon 2054, Becton Dickinson Lab Ware, Bedford, MA) coated with GAM. For coating of GAM to the tubes, 100 μL of GAM in coating buffer (100 μg/mL in 30 mmol/L NaHCO3, 15 mmol/L Na2CO3, pH 9.6) was added to each tube, incubated 1 hour at 37°C, and washed five times with Hanks' Balanced Salt Solution (HBSS). Treatment of cells with gp120 (5 μg/mL) followed by culture with immobilized anti-gp120 antibodies (10 μg/mL) was performed in a procedure identical to that described for Leu3a/GAM.

Lymphocyte  surface  phenotype  and  cytoplasmic  staining. Lymphocyte surface markers were identified by triple-color immunofluorescence using various combinations of MoAbs. The MoAbs were conjugated with phycoerythrin (PE) or peridinin chorophyII A (PerCP) as indicated: PerCP-CD8 (IgG2a), PE-CD14 (IgG2b), PerCP-CD45 (IgG1), and PE- or PerCP-CD3 (IgG1); all MoAbs and relevant isotype-matched control MoAbs were purchased from Becton Dickinson Immunocytometry Systems (San Jose, CA). PE-Fas (clone UB2, IgG1) was obtained from Immunotec Inc (Westbrook, ME). Surface staining was performed at room temperature for 10 minutes in cells suspended in staining buffer (HBSS containing 1% FCS and 0.1% sodium azaide). For intracytoplasmic staining, cells were fixed following surface staining with 1% paraformaldehyde in HBSS, washed, and permeabilized for 10 minutes with saponin (Sigma Chemicals, St Louis, MO) at a concentration of 0.1% (wt/vol) in permeabilization buffer (PB; 10 mmol/L HEPES in HBSS). fluorescein isothiocyanate (FITC)-labeled antihuman Bcl-2 (IgG1, DAKO, Carpinteria, CA) was used for cytoplasmic direct staining. Bax (Bax N-20; Santa Cruz Biotechnology, Santa Cruz, CA) was used for indirect staining with PE-labeled goat antirabbit IgG (Caltag Laboratories, Burlingame, CA). Normal mouse and rabbit IgG were used as negative controls for staining. Cells were washed with PB, resuspended in 1% paraformaldehyde HBSS, and analyzed by flow cytometry using the Epics Elite instrument (Coulter Corp, Hialeah, FL).

Analysis of lymphocyte apoptosis.Two methods were used to identify apoptotic cells at 72 hours after culture: (1) light scatter of cells gated for CD3 or CD45 and subpopulation-specific marker, which allowed the analysis of surface phenotype of cells undergoing apoptosis,3,25,26 and (2) propidium iodide (PI) staining, which was performed as described.3 13 In brief, cells were fixed in 75% ethanol for 1 hour at 4°C, washed and resuspended in HBSS containing PI (50 μg/mL, Molecular Probes, Eugene, OR) and ribonuclease A (type I-A, Sigma, 250 μg/mL). The PI fluorescence of cells in the lymphocyte-gate was measured at 48 to 72 hours poststaining by flow cytometry.

CD4 cross-linking downmodulates Bcl-2 expression. To determine the effect of CD4XL on Bcl-2 expression, sequential analysis of Bcl-2 expression was performed after CD4XL in PBMC from HIV-seronegative healthy volunteers. As shown in Fig 1, CD4XL clearly reduced Bcl-2 expression in CD3+T cells on days 2, 3, and 5 (Bcl-2dim cells 20.7%, 23.3%, and 24.6%, respectively). In contrast, cells in medium or those treated with mouse Ig/GAM showed minimal downmodulation of Bcl-2 on day 3 (2.3% and 5.6%, respectively). The net percentages of Bcl-2dim population in the CD4XL samples after subtracting out mIg controls were 13.8%, 17.7%, and 10.7% on days 2, 3, and 5, respectively. Moreover, the Bcl-2 downmodulation was not observed with Leu3a treatment or GAM treatment alone on day 3 (4.1% and 8.4%, respectively). In subsequent experiments, we evaluated CD4XL-PBMC on day 3 of culture.

Fig. 1.

Time course of Bcl-2 downmodulation after CD4 cross-linking. PBMC, treated as indicated, were cultured for 1, 2, 3, and 5 days. Cells were analyzed by flow cytometry for intracytoplasmic Bcl-2 expression in conjunction with surface staining with PE-labeled CD3 MoAb and per-CP–labeled CD45 MoAb. Broken and solid lines indicate the notch of the Bcl-2 downmodulation and the uppermost boundary of the isotype control, respectively. Percentages indicated in the figure are percentages of Bcl-2dim plus Bcl-2 negative cells (almost all were Bcl-2dim).

Fig. 1.

Time course of Bcl-2 downmodulation after CD4 cross-linking. PBMC, treated as indicated, were cultured for 1, 2, 3, and 5 days. Cells were analyzed by flow cytometry for intracytoplasmic Bcl-2 expression in conjunction with surface staining with PE-labeled CD3 MoAb and per-CP–labeled CD45 MoAb. Broken and solid lines indicate the notch of the Bcl-2 downmodulation and the uppermost boundary of the isotype control, respectively. Percentages indicated in the figure are percentages of Bcl-2dim plus Bcl-2 negative cells (almost all were Bcl-2dim).

Close modal

In our previous study, we observed that a loss of cellular volume (forward scatter: [FSC]) and an increase in cellular density (side scatter: [SSC]) is a characteristic feature of cells undergoing apoptosis.6 25 Thus, we examined the Bcl-2 expression in low FSC/high SSC fraction (Apoptotic lymphocyte fraction: [Apo Fr.]) and in the high FSC/low SSC (Intact lymphocyte fraction: [Int Fr.]). As shown in Fig 2A, cells in the Apo Fr. were found to be composed principally of Bcl-2dim cells, while the Int Fr. clearly expressed a single high Bcl-2 peak. Mean fluorescence intensity (MFI) in Apo Fr. was significantly lower as compared to MFI in the Int Fr. (Fig 2B). These results suggest that downmodulation of Bcl-2, which is known to act as an apoptosis-repressor, might play a critical role in CD4XL-induced apoptosis.

Fig. 2.

Bcl-2 downmodulated lymphocyte population is undergoing apoptosis. The Bcl-2 expression of cells in CD4XL-PBMC was analyzed on day 3. (A) Based on the light scatter profiles, the low FSC/high SSC Apo Fr. was compared with high FSC/low SSC Int Fr. Histograms of Bcl-2 in the total lymphocyte fraction [box 3 (medium), box 4 (CD4XL)], and after CD4XL in Apo Fr. (box 5) and Int Fr. (box 6) are indicated. (B) Comparison of the MFI level of Bcl-2 between the apoptotic and intact lymphocyte fractions (n = 9). Values of statistical significance determined by paired t test are indicated.

Fig. 2.

Bcl-2 downmodulated lymphocyte population is undergoing apoptosis. The Bcl-2 expression of cells in CD4XL-PBMC was analyzed on day 3. (A) Based on the light scatter profiles, the low FSC/high SSC Apo Fr. was compared with high FSC/low SSC Int Fr. Histograms of Bcl-2 in the total lymphocyte fraction [box 3 (medium), box 4 (CD4XL)], and after CD4XL in Apo Fr. (box 5) and Int Fr. (box 6) are indicated. (B) Comparison of the MFI level of Bcl-2 between the apoptotic and intact lymphocyte fractions (n = 9). Values of statistical significance determined by paired t test are indicated.

Close modal

CD4 cross-linking does not change the Bax expression even in the Bcl-2dim population.Bax is known to antagonize the survival promoting effects of Bcl-227 and forms a heterodimer with Bcl-2. Thus, we sought to determine Bax expression in CD4XL-PBMC. To detect both Bcl-2 and Bax proteins at the single cell level, we employed simultaneous cytoplasmic staining of both Bcl-2 and Bax proteins, as well as CD3 surface staining. As shown in Fig 3, 95% of CD3+ cells cultured in medium alone coexpressed both Bcl-2 and Bax proteins. Upon CD4XL, Bcl-2 expression was downmodulated in approximately 20% of CD3+ cells. In contrast, Bax protein was expressed in high levels even in the Bcl-2 downmodulated population. However, we failed to detect high Bcl-2 expression in Bax negative cells.

Fig. 3.

Bax expression is unchanged in CD4 cross-linked PBMC. Intracytoplasmic staining of Bcl-2 and Bax was performed with surface CD3 staining on day 3. Three representative results of Bcl-2 and Bax expression in CD3+ T cells are demonstrated.

Fig. 3.

Bax expression is unchanged in CD4 cross-linked PBMC. Intracytoplasmic staining of Bcl-2 and Bax was performed with surface CD3 staining on day 3. Three representative results of Bcl-2 and Bax expression in CD3+ T cells are demonstrated.

Close modal

Bcl-2 expression is reduced in CD4+ T cells but not in CD8+ T cells.We next examined the effect of CD4XL on Bcl-2 expression in different T-cell subsets. As previously reported, CD4+ cells are undetectable by staining with anti-CD4 MoAb in the CD4XL samples.3 Thus, we examined intracytoplasmic Bcl-2 with FITC-Bcl–2 in conjunction with PE-CD3 and Per-CP-CD8 for evaluating cell surface antigens. We observed Bcl-2 downmodulation only in the CD8- CD3+ lymphocyte subset, whereas Bcl-2 was expressed as a single high peak in the CD3+CD8+ lymphocyte subset (Fig 4). Moreover, we confirmed that Bcl-2 downmodulation occurs predominantly in CD4+ T cells following CD4XL using HIV-gp120, as well. Bcl-2 downmodulation was noted to occur in approximately 40% to 50% of the CD4+ T cells, which is in agreement with the percentage of CD4+ T cells undergoing CD4XL-induced apoptosis.7 

Fig. 4.

Bcl-2 downmodulation by CD4XL in PBMC is restricted to CD4+ T cells. Intracytoplasmic Bcl-2 staining was performed on day 3 in combination with surface CD8 and CD3 staining in the CD4XL-PBMC. Histograms representing the Bcl-2 expression in (CD3+CD8+, and CD3+CD8-) gated populations are shown. The vertical line indicates the notch of the Bcl-2 downmodulation in CD3+CD8- cells.

Fig. 4.

Bcl-2 downmodulation by CD4XL in PBMC is restricted to CD4+ T cells. Intracytoplasmic Bcl-2 staining was performed on day 3 in combination with surface CD8 and CD3 staining in the CD4XL-PBMC. Histograms representing the Bcl-2 expression in (CD3+CD8+, and CD3+CD8-) gated populations are shown. The vertical line indicates the notch of the Bcl-2 downmodulation in CD3+CD8- cells.

Close modal

Bcl-2 downmodulation was observed in Fas positive population.We previously reported that Fas antigen expression is upregulated in lymphocytes by CD4XL.6 To investigate the distribution of Fas in relation to Bcl-2 expression, we examined surface Fas antigen expression in Bcl-2dim and Bcl-2high populations in the CD4XL-PBMC. As shown in Fig 5, we confirmed the upregulation of Fas antigen expression even in the Bcl-2high population in CD4XL-PBMC as compared with medium-treated cells. Moreover, the single peak indicating high expression of Fas antigen was clearly demonstrated in the Bcl-2dim population. Cells stimulated by PHA expressed high Fas antigen, but with minimal downmodulation of Bcl-2 expression.

Fig. 5.

Fas expression is increased in CD4XL-PBMC in the Bcl-2dim population. PBMC were treated with medium, Leu3a/GAM, or PHA for 3 days and intracytoplasmic Bcl-2 staining was performed in combination with surface Fas antigen and CD3 staining. Fas expression was evaluated separately in Bcl-2dim and Bcl-2high cells gated on the CD3+ cell population.

Fig. 5.

Fas expression is increased in CD4XL-PBMC in the Bcl-2dim population. PBMC were treated with medium, Leu3a/GAM, or PHA for 3 days and intracytoplasmic Bcl-2 staining was performed in combination with surface Fas antigen and CD3 staining. Fas expression was evaluated separately in Bcl-2dim and Bcl-2high cells gated on the CD3+ cell population.

Close modal

Exogenous IL-2 blocks CD4 cross-linking–induced apoptosis.It has been previously reported that IL-2 receptor-dependent signaling pathway induces Bcl-2.28 Moreover, exogenous IL-2 induces Bcl-2 and rescues cells from apoptosis.29-32 We previously reported that CD4XL induces IFN-γ and TNF-α, but not IL-2 secretion. Thus, we sought to determine the effects of IL-2 on CD4XL-induced apoptosis. IL-2 was added to PBMC at initiation of CD4XL and the emergence of subdiploid nuclei (% A0 cells) was evaluated in the PI-stained sample. As shown in Fig 6A, exogenous IL-2 significantly decreased the % A0 cells in CD4XL-PBMC cultures on day 2 and day 3, but no increase was observed in the S phase in PI staining at this time. In addition, exogenous IL-2 did not increase net cell counts during the 3-day culture period of CD4XL (data not shown). Thus, the significant decrease in the % A0 cells (Fig 6B), is attributable to the apoptosis blocking effect of IL-2 and does not occur as a result of cell division. As shown in Fig 7, IL-2 also prevented the CD4XL-related Bcl-2 downmodulation in the peripheral T cells. Moreover, the prevention of the Bcl-2 downmodulation was clearly associated with the decrease in the % A0 cells. Thus, the rescue of cells from apoptosis by IL-2 occurs in association with a reduction in the Bcl-2dim lymphocyte population.

Fig. 6.

IL-2 rescues CD4XL cells from apoptosis. (A) Time course study of the effect of IL-2 on CD4 cross-linking induced-apoptosis. PBMC treated with or without Leu3a/GAM were cultured in the absence or presence of IL-2 (30 U/mL). Cells were harvested on days 1, 2, and 3 after treatment and analyzed for the percent of A0 cells by flow cytometry. The percentages of A0 cells (% A0) are indicated in the histograms. (B) Comparison of the % A0 cells in CD4XL samples with and without addition of IL-2. The (□) indicate results on day 2 (n = 4) and the (•) indicate results on day 3 (n = 4) after CD4XL. Values of statistical significance determined by paired t test are indicated.

Fig. 6.

IL-2 rescues CD4XL cells from apoptosis. (A) Time course study of the effect of IL-2 on CD4 cross-linking induced-apoptosis. PBMC treated with or without Leu3a/GAM were cultured in the absence or presence of IL-2 (30 U/mL). Cells were harvested on days 1, 2, and 3 after treatment and analyzed for the percent of A0 cells by flow cytometry. The percentages of A0 cells (% A0) are indicated in the histograms. (B) Comparison of the % A0 cells in CD4XL samples with and without addition of IL-2. The (□) indicate results on day 2 (n = 4) and the (•) indicate results on day 3 (n = 4) after CD4XL. Values of statistical significance determined by paired t test are indicated.

Close modal
Fig. 7.

Downmodulation of Bcl-2 expression is prevented by IL-2. PBMC treated with Leu3a/GAM were cultured in the absence or presence of IL-2 (30 U/mL) for 3 days. The percentages indicated in the figure are percentages of the Bcl-2 dim plus Bcl-2 negative cells. Values of statistical significance determined by paired t test are indicated (n = 6).

Fig. 7.

Downmodulation of Bcl-2 expression is prevented by IL-2. PBMC treated with Leu3a/GAM were cultured in the absence or presence of IL-2 (30 U/mL) for 3 days. The percentages indicated in the figure are percentages of the Bcl-2 dim plus Bcl-2 negative cells. Values of statistical significance determined by paired t test are indicated (n = 6).

Close modal

We previously demonstrated that CD4XL in PBMC results in induction of CD4+ T-cell apoptosis in conjunction with generalized Fas antigen upregulation in lymphocytes6 and have recently shown that CD4XL leads to enhanced FasL expression in monocytes.7 Although Fas and FasL expression reached high levels as early as day 1 after CD4XL, numbers of lymphocytes undergoing apoptosis were still low on day 1 and increased to high levels by day 3 (Fig 6A). This discrepancy between the time of Fas upregulation and induction of apoptosis led us to examine the expression of Bcl-2 protein, which is known to be an inhibitor of apoptosis. In this report, we show that the Bcl-2 expression is reduced on day 3 after CD4XL, but not on day 1 (Fig 1), and that the cells undergoing apoptosis are composed primarily of the Bcl-2dim population (Fig 2). Furthermore, despite the augmentation of Fas expression, the number of apoptotic cells resulting from CD4XL were significantly decreased in the presence of exogenous IL-2 (Fig 6), and the reduction in apoptosis correlated with a reversal of Bcl-2 downmodulation. These results suggest that although the upregulation of Fas and FasL expression facilitates CD4XL-induced apoptosis, the downmodulation of Bcl-2 is essential for the conduct of apoptosis.

Recently, Desbarats et al33 reexamined CD4XL-induced apoptosis in murine CD4+ T cells. They noted that although anti-CD4 MoAb-treated and untreated cells expressed equivalent amounts of surface Fas antigen, only the CD4 MoAb-treated cells were susceptible to anti-Fas–mediated increase in cell death. The investigators concluded that CD4XL alters the sensitivity of CD4+ cells to Fas-induced death. Our data suggests that Bcl-2 downmodulation in CD4XL-cells renders them sensitive for Fas-induced apoptosis.

The capacity of Bax and Bcl-2 to compete for one another suggests a reciprocal relationship in which Bcl-2 monomers or homodimers favor survival and Bax homodimers favor death.27 Our results show that most of the normal peripheral T cells were Bcl-2+ Bax+ in day 3-medium–treated cultures (Fig 3) and in freshly isolated PBMC (data not shown). Also, we found that Bax expression was still high even in the Bcl-2dim population. Thus, in normal PBMC, almost all peripheral T cells appear to be in a stable state of Bcl-2/Bax heterodimers, whereas the Bcl-2dim population may be indicative of formation of Bax/Bax homodimers in cells undergoing apoptosis. However, we failed to observe an increase in Bcl-2+/Bax- cell population even with the addition of IL-2 (data not shown). Although it remains controversial whether Fas-induced apoptosis can be rescued by overexpression of Bcl-2,34 35 we did not observe a cell population in our system that expressed higher Bcl-2 than that in resting cells.

The biologic relevance of our studies is particularly applicable to HIV disease. Uninfected and latently infected CD4+ cells in HIV-infected subjects have the potential to undergo CD4 cross-linking in vivo by HIV envelope protein, either as expressed on infected cells or by free gp120 or via virions trapped within the processes of dendritic cells in lymph nodes. In this study, we show that the Bcl-2dim lymphocyte cells, which undergo apoptosis on in vitro CD4XL, are contained in the CD4+ T-cell subset, but not in the CD8+ T-cell population. Furthermore, we confirmed this restriction of Bcl-2 distribution in cells subjected to CD4XL with HIV gp120. This finding should be considered in the context of observations made in infected individuals. Patients with HIV infection manifest augmented lymphocyte apoptosis of CD4+ T, CD8+ T, and B lymphocytes. Moreover, we have recently observed that the Bcl-2 downmodulation of cultured PBMC from HIV+ patients was not restricted to CD4+ T cells, but was observed in CD8+ T cells and also in B cells.25 These apparent disparities between results in patients' peripheral blood and the effect of in vitro CD4XL of normal CD4+ T cells can be explained by the possibility that in HIV infection, at least two mechanisms are involved in induction of generalized lymphocyte apoptosis. Superimposed on the mechanism of apoptotic CD4+ T-cell death induced by CD4XL, is another mechanism for apoptosis attributable to Fas/FasL upregulation and Bcl-2 downmodulation in terminally differentiated- and senescent lymphocytes of HIV+ patients as a result of chronic persistent infection. The importance of the CD4XL mechanism as a primary driving force for lymphocyte apoptosis is nevertheless underscored by our previous demonstration that CD4XL resulted in augmented Fas antigen expression, not only in CD4+ T cells, but also in CD8+ T cells and in B cells as well.6 

The downmodulation of Bcl-2 expression, which was restricted to CD4+ T cells in CD4XL-PBMC could not, of itself, be attributed to induced cytokines TNF-α and IFN-γ, which were shown to play a central role in the generalized upregulation of Fas antigen on various lymphocytes subsets.6 One explanation for the observed downmodulation of Bcl-2 is that attributable directly to CD4 signaling effects; another possibility is that CD4 ligation results in a decrease in IL-2 production in CD4+ T cells but not in CD8+ T cells, thereby leading to Bcl-2 downmodulation in an autocrine manner. Although this issue is under investigation, the absence of IL-2 induction by CD4XL3 and the inability of gp120-treated CD4+ T cells to secrete IL-2 in response to antigenic stimulation,36 implicate an important role for IL-2 deficiency in the induction of lymphocyte apoptosis. Finally, the observed effects of IL-2 in blocking CD4XL-induced apoptosis were closely associated with blocking of the CD4XL-induced downmodulation of Bcl-2 expression (Fig 7). As recent reports show,29,31 this finding strongly suggests that IL-2 mediates its apoptosis-blocking effects via prevention of the downmodulation of Bcl-2 protein. Recent clinical trials of IL-2 in HIV-positive individuals37 38 have showed that although no significant change occurred in plasma HIV concentrations with IL-2 therapy, CD4+ T cells increased in a dose-dependent manner. The data reported herein support the findings of the clinical trial and implicate that rescue from apoptosis may be a mechanism for the observed increase in CD4+ T cells. However, the addition of exogenous IL-2 in our experimental system only partially blocked the apoptosis resulting from CD4XL. Additional mechanisms underlying the CD4XL-induced apoptosis, such as failure of Bcl-xL induction and measures to counteract these effects need further investigation.

We thank Dr Thomas W McCloskey for helpful discussions.

Supported by Grants No. AI 12828 and DA 05161 from the National Institutes of Health, Bethesda, MD.

Address reprint requests to Savita Pahwa, MD, Biomedical Research Building, Department of Pediatrics, North Shore University-New York University School of Medicine, 350 Community Dr, Manhasset, NY 11030.

1
Meyaard
L
Otto
SA
Jonker
RR
Mijnster
MJ
Keet
RP
Miedema
F
Programmed death of T cells in HIV-1 infection.
Science
257
1992
217
2
Groux
H
Torpier
G
Monte
D
Mouton
Y
Capron
A
Ameisen
JC
Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals.
J Exp Med
175
1992
331
3
Oyaizu
N
McCloskey
TW
Coronesi
M
Chirmule
N
Kalyanaraman
VS
Pahwa
S
Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals.
Blood
82
1993
3392
4
Muro-Cacho
CA
Pantaleo
G
Fauci
AS
Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden.
J Immunol
154
1995
5555
5
Finkel
TH
Tudor-Williams
G
Banda
NK
Cotton
MF
Curiel
T
Monks
C
Baba
TW
Ruprecht
RM
Kupfer
A
Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes [see comments].
Nat Med
1
1995
129
6
Oyaizu
N
McCloskey
TW
Than
S
Hu
R
Kalyanaraman
VS
Pahwa
S
Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion.
Blood
84
1994
2622
7
Oyaizu
N
Adachi
Y
Hashimoto
F
McCloskey
TW
Hosaka
N
Kayagaki
N
Yagita
H
Pahwa
S
Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: A possible mechanism of bystander cell death in HIV infection.
J Immunol
158
1997
2456
8
Baumler
CB
Bohler
T
Herr
I
Benner
A
Krammer
PH
Debatin
KM
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children.
Blood
88
1996
1741
9
Gehri
R
Hahn
S
Rothen
M
Steuerwald
M
Nuesch
R
Erb
P
The Fas receptor in HIV infection: Expression on peripheral blood lymphocytes and role in the depletion of T cells.
AIDS
10
1996
9
10
Estaquier
J
Tanaka
M
Suda
T
Nagata
S
Golstein
P
Ameisen
JC
Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: Differential in vitro preventive effect of cytokines and protease antagonists.
Blood
87
1996
4959
11
Gougeon
ML
Lecoeur
H
Dulioust
A
Enouf
MG
Crouvoiser
M
Goujard
C
Debord
T
Montagnier
L
Programmed cell death in peripheral lymphocytes from HIV-infected persons: Increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression.
J Immunol
156
1996
3509
12
Katsikis
PD
Wunderlich
ES
Smith
CA
Herzenberg
LA
Herzenberg
LA
Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals.
J Exp Med
181
1995
2029
13
McCloskey
TW
Oyaizu
N
Kaplan
M
Pahwa
S
Expression of the Fas antigen in patients infected with human immunodeficiency virus.
Cytometry
22
1995
111
14
Wyllie
AH
Apoptosis. Death gets a brake [news; comment].
Nature
369
1994
272
15
Henkart
PA
Apoptosis: O death, where is thy sting?
J Immunol
154
1995
4905
16
Nunez
G
Merino
R
Grillot
D
Gonzalez-Garcia
M
Bcl-2 and Bcl-x: Regulatory switches for lymphoid death and survival.
Immunol Today
15
1994
582
17
Tsujimoto
Y
Croce
CM
Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.
Proc Natl Acad Sci USA
83
1986
5214
18
Cleary
ML
Smith
SD
Sklar
J
Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14; 18) translocation.
Cell
47
1986
19
19
Iwai
K
Miyawaki
T
Takizawa
T
Konno
A
Ohta
K
Yachie
A
Seki
H
Taniguchi
N
Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils.
Blood
84
1994
1201
20
Mapara
MY
Bargou
R
Zugck
C
Dohner
H
Ustaoglu
F
Jonker
RR
Krammer
PH
Dorken
B
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl-2 oncogene expression.
Eur J Immunol
23
1993
702
21
Salmon
M
Pilling
D
Borthwick
NJ
Viner
N
Janossy
G
Bacon
PA
Akbar
AN
The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis.
Eur J Immunol
24
1994
892
22
Yoshino
T
Kondo
E
Cao
L
Takahashi
K
Hayashi
K
Nomura
S
Akagi
T
Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes.
Blood
83
1994
1856
23
Miyawaki
T
Uehara
T
Nibu
R
Tsuji
T
Yachie
A
Yonehara
S
Taniguchi
N
Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood.
J Immunol
149
1992
3753
24
Kalyanaraman
VS
Rodriguez
V
Veronese
F
Rahman
R
Lusso
P
De Vico
AL
Copeland
T
Oroszlan
S
Gallo
RC
Sarngadharan
MG
Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1.
AIDS Res Hum Retroviruses
6
1990
371
25
Adachi
Y
Oyaizu
N
Than
S
McCloskey
TW
Pahwa
S
IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: Correlation with its ability to block culture-induced down-modulation of Bcl-2.
J Immunol
157
1996
4184
26
Loken
MR
Brosnan
JM
Bach
BA
Ault
KA
Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry.
Cytometry
11
1990
453
27
Oltvai
ZN
Milliman
CL
Korsmeyer
SJ
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
Cell
74
1993
609
28
Miyazaki
T
Liu
ZJ
Kawahara
A
Minami
Y
Yamada
K
Tsujimoto
Y
Barsoumian
EL
Permutter
RM
Taniguchi
T
Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation.
Cell
81
1995
223
29
Akbar
AN
Borthwick
NJ
Wickremasinghe
RG
Panayoitidis
P
Pilling
D
Bofill
M
Krajewski
S
Reed
JC
Salmon
M
Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: Selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression.
Eur J Immunol
26
1996
294
30
Mueller
DL
Seiffert
S
Fang
W
Behrens
TW
Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells.
J Immunol
156
1996
1764
31
Mor
F
Cohen
IR
IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2.
J Immunol
156
1996
515
32
Deng
G
Podack
ER
Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2.
Proc Natl Acad Sci USA
90
1993
2189
33
Desbarats
J
Freed
JH
Campbell
PA
Newell
MK
Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells.
Proc Natl Acad Sci USA
93
1996
11014
34
Lee
RK
Spielman
J
Podack
ER
bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis.
Int Immunol
8
1996
991
35
Chiu
VK
Walsh
CM
Liu
CC
Reed
JC
Clark
WR
Bcl-2 blocks degranulation but not fas-based cell-mediated cytotoxicity.
J Immunol
154
1995
2023
36
Oyaizu
N
Chirmule
N
Kalyanaraman
VS
Hall
WW
Pahwa
R
Shuster
M
Pahwa
S
Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA [published erratum appears in Proc Natl Acad Sci USA 87:4022, 1990].
Proc Natl Acad Sci USA
87
1990
2379
37
Jacobson
EL
Pilaro
F
Smith
KA
Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity.
Proc Natl Acad Sci USA
93
1996
10405
38
Kovacs
JA
Vogel
S
Albert
JM
Falloon
J
Davey
R Jr
Walker
RE
Polis
MA
Spooner
K
Metcalf
JA
Baseler
M
Fyfe
G
Lane
HC
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
N Engl J Med
335
1996
1350
Sign in via your Institution